PHAXIAM Therapeutics (XPAR:PHXM) Price-to-Owner-Earnings : (As of May. 19, 2024)

View and export this data going back to 2013. Start your Free Trial

What is PHAXIAM Therapeutics Price-to-Owner-Earnings?

As of today (2024-05-19), PHAXIAM Therapeutics's share price is €3.055. PHAXIAM Therapeutics does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.

The historical rank and industry rank for PHAXIAM Therapeutics's Price-to-Owner-Earnings or its related term are showing as below:

XPAR:PHXM's Price-to-Owner-Earnings is not ranked ^*
in the Biotechnology industry.
Industry Median: 35.58
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-19), PHAXIAM Therapeutics's share price is €3.055. PHAXIAM Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was €0.98. Therefore, PHAXIAM Therapeutics's PE Ratio for today is 3.13.

As of today (2024-05-19), PHAXIAM Therapeutics's share price is €3.055. PHAXIAM Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in was €0.96. Therefore, PHAXIAM Therapeutics's PE Ratio without NRI for today is 3.19.

During the past 11 years, PHAXIAM Therapeutics's highest PE Ratio without NRI was 7.72. The lowest was 0.00. And the median was 0.00.

PHAXIAM Therapeutics Price-to-Owner-Earnings Historical Data

The historical data trend for PHAXIAM Therapeutics's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PHAXIAM Therapeutics Price-to-Owner-Earnings Chart

PHAXIAM Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Owner-Earnings

Get a 7-Day Free Trial

PHAXIAM Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23
Price-to-Owner-Earnings	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of PHAXIAM Therapeutics's Price-to-Owner-Earnings

For the Biotechnology subindustry, PHAXIAM Therapeutics's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PHAXIAM Therapeutics's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PHAXIAM Therapeutics's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where PHAXIAM Therapeutics's Price-to-Owner-Earnings falls into.

PHAXIAM Therapeutics Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

PHAXIAM Therapeutics's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings	=	Share Price	/	Owner Earnings per Share (TTM)
	=	3.055	/	-3.34
	=

PHAXIAM Therapeutics (XPAR:PHXM) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.

PHAXIAM Therapeutics Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of PHAXIAM Therapeutics's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.

PHAXIAM Therapeutics (XPAR:PHXM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PHAXIAM Therapeutics SA (XPAR:PHXM) » Definitions » Price-to-Owner-Earnings

Comparable Companies

Traded in Other Exchanges

PHXM:USA 2E41:Germany

Address

60 Avenue Rockefeller, Lyon, FRA, 69008

Website

https://www.erytech.com

Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate. The company is developing eryaspase for the treatment of severe tumors, including pancreatic cancer, acute lymphoblastic leukemia, or ALL, and triple negative breast cancer, or TNBC.